| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Intratracheal injection of bleomycin 2 mg/kg (low dose) and 10 mg/kg (high dose) induced fibrotic lung lesions and hemorrhagic lung lesions, respectively. Thus, mice models of rapidly progressive interstitial pneumonia have been established.
Moreover, a 3-dimensional mixed culture of human lung epithelial cells and human pulmonary fibroblasts was used as a screening test for novel therapeutic agents for rapidly progressive interstitial pneumonia. Imatinib, a drug for chronic myeloid leukemia, selectively inhibited the proliferation of pulmonary fibroblasts stimulated by platelet-derived growth factor.
These results elucidated the possible treatment of rapidly progressive interstitial pneumonia by targeted therapies.
|
